Ahmad Tarhini, MD, PhD


Titles and Roles

Acting Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Co-Director, Melanoma and Skin Cancers Program
Winship Cancer Institute of Emory University
Medical Oncologist
Ocular Melanoma
Phase I Clinical Trials Unit
Research Program
Discovery and Developmental Therapeutics


Ahmad Tarhini, MD, PhD is Acting Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Tarhini serves as co-director of the Melanoma and Skin Cancers Program at Winship Cancer Institute of Emory University. Board certified in medical oncology, Dr. Tarhini specializes in the treatment of melanoma (cutaneous, uveal and mucosal) and other skin cancers including Merkel cell carcinoma, squamous cell carcinoma and basal cell carcinoma.

Prior to arriving at Emory, he served on faculty at University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, and Case Western Reserve University and Cleveland Clinic Lerner School of Medicine in Cleveland, Ohio.

Dr. Tarhini is a member of the Discovery and Developmental Therapeutics research program at Winship Cancer Institute. He holds professional memberships with American Society of Clinical Oncology, American Association of Cancer Research, Cytokine Working Group, Eastern Cooperative Oncology Group, Society for Clinical and Translational Science, and Society for Immunotherapy of Cancer.


Dr. Tarhini received his medical degree from Kaunas University of Medicine. He received his master of science degree in clinical research and doctorate degree in clinical and translational science from the University of Pittsburgh School of Medicine where he also completed both his residency in internal medicine and his hematology and oncology fellowship.


Funded through the National Institutes of Health and other mechanisms, Dr. Tarhini's translational research work studies biomarkers of prognosis and therapeutic benefit in melanoma. As a principal investigator, he leads multiple national clinical trials and biomarker studies in the field of immuno-oncology, and has investigated the role of promising biomarkers in relation to disease risk and clinical benefits of immunotherapy in the melanoma adjuvant, neoadjuvant, and advanced disease settings. His clinical research expertise involves Phase I, II and III clinical trials. This is in addition to his work involving health economics outcomes research.

Dr. Tarhini serves as a chair/co-chair on several cooperative group trials, including U.S. Intergroup clinical trials E1609, S1404, EA6141, E3612, E3611, NCI8628 and NCI10061.


Dr Tarhini's original work on immunotherapy of melanoma and biomarkers of disease prognosis and therapeutic benefit has been published in high-impact, peer-reviewed journals, and presented at leading national and international meetings. He currently serves on the editorial board of Oncology.

  • PublicationsPublication Date


Dr. Tarhini has received multiple awards including the University of Pittsburgh Cancer Institute Junior Scholar Award and the Eastern Cooperative Oncology Group Young Investigator Award.

Additional Websites

Cascade Link   TOP